Sarah Kleinstein is a Ph.D. candidate in the Department of Molecular Genetics and Microbiology at Duke University, currently studying under Dr. David Goldstein in the Institute for Genomic Medicine at Columbia University. Her primary research focus is determining the genetic underpinnings behind differential responses to infectious diseases, such as HIV-1, HSV-2, HCV, and HBV. Kleinstein also holds a BS in Biochemistry and an MS in Genetic Epidemiology (both from the University of Washington, Seattle). Her undergraduate research involved elucidating causal mutations related to the Muscular Dystrophy phenotypes observed in mutant Drosophila melanogaster. Her MS research investigated genetic susceptibility to colorectal neoplasia and genetic interactions with nonsteroidal anti-inflammatory drug use in the lipoxygenase pathway at the Fred Hutchinson Cancer Research Center. After finishing her MS, Sarah completed a one year Centers for Disease Control and Prevention and Association of Public Health Laboratories joint fellowship in Emerging Infectious Diseases. During her fellowship, she worked at the California Department of Public Health Microbial Diseases Laboratory, characterizing emerging multi-drug resistance in a Salmonella Typhimurium outbreak and validating a new cpn60 gene target for broad range sequence-based bacterial identification.